IGF2BP2 and type 2 diabetes mellitus: Based on the results of our study, we conclude that the effect of common polymorphisms in IGF2BP2, HHEX, CDKN2A/B, SLC30A8, PPARG, and KCNJ11, all of which have been previously associated with T2DM, is not pronounced in the risk of NODAT in kidney transplant recipients treated with tacrolimus.